Tscan Therapeutics is trading at $0.83, up 5.64%, with no clear company-specific announcement, filing, analyst action, or clinical catalyst identified for August 18, 2026.
- Latest company news was second-quarter results released August 12, including $1.05 million revenue and a $0.23-per-share adjusted loss.
- Market-wide risk-off pressure saw the Nasdaq decline 1.1% as oil and bond yields rose amid U.S.-Iran tensions.